Efficiency Improvements and Selective Focus in Existing Businesses
First written in FY2024. 8 of 10 entries say "Advanced", first in FY2025. Latest entry: 2026-10-14.
0 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「To address this issue, the Company established and began operating a portfolio meeting and a Sales & Operations Planning (S&OP) process, as well as a new Life Cycle Management (LCM) meeting aimed at maximising product value after launch.」
Regarding efficiency in existing businesses, the Company introduced and began operating portfolio, S&OP and LCM meetings, giving concrete form to governance reform. It also disclosed a new consortium concept, including the transfer of the generic drug business. - FY2025AdvancedAnnual report
「Led by the Portfolio Management Department, the Company will promote “selection and concentration” among existing products and seek to improve profit margins by using available production capacity and human resources to manufacture high-value-added products. It has also introduced an S&OP (Sales & Operations Planning) process to maintain an appropriate supply-demand balance, optimise production efficiency and minimise waste, and promote collaboration among teams.」
In addition to selection and concentration led by the Portfolio Management Department, the Company introduced an S&OP process. It also disclosed that discussions with Meiji Seika Pharma began in June 2025 regarding the integration of product items and related matters. - FY2024First statedAnnual report
「To address this issue, the Company newly established a Portfolio Management Department directly under the president. Led by this department, the Company will promote “selection and concentration” among existing products and seek to improve profit margins by using available production capacity and human resources to manufacture high-value-added products.」
The Company disclosed for the first time measures to shift its focus from expansion through its traditional all-around business model to selection and concentration among existing products led by the Portfolio Management Department, reallocating available capacity to high-value-added products, improving production efficiency, strengthening quality assurance and reviewing its development strategy.